To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00881179

Enrollment

Registered

2009-04-15

Start date

2002-05-31

Completion date

2002-06-30

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Antibiotic

Brief summary

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Interventions

DRUGClarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)

DRUGBiaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 59 Years

Healthy volunteers

Yes

Inclusion criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

* Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.

Design outcomes

Primary

Measure	Time frame
Bioequivalence based on AUC and Cmax	9 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026